Hitting the BCMA Target in Multiple Myeloma

Betting on BCMA Therapy in Multiple MyelomaПодробнее

Using BCMA-targeting agents in earlier lines of treatment for multiple myelomaПодробнее

BCMA-Targeted Therapies in Multiple MyelomaПодробнее

Dr. Stadtmauer on BCMA-Targeting in Multiple MyelomaПодробнее

CAR T-cells in Multiple MyelomaПодробнее

Incorporating BCMA-targeted CAR-T therapy in the frontline treatment of multiple myelomaПодробнее

Spotlight on BCMA: A Major Target for Multiple MyelomaПодробнее

Relapsed Therapy and Clinical Trials - Dr. Caitlin Costello: RCW San Diego 2021Подробнее

Treating multiple myeloma resistant to BCMA-targeted therapyПодробнее

Dr. Cortes on the Advantage of BCMA-Targeted Therapy in Multiple MyelomaПодробнее

What Is BCMAПодробнее

BCMA in Multiple Myeloma: Emerging Targeted SolutionsПодробнее

BCMA-targeted BiTEs for multiple myelomaПодробнее

Anti-BCMA Bispecific Antibody for Myeloma Relapse After CAR T CellsПодробнее

Managing progression after BCMA-targeted therapy in R/R multiple myelomaПодробнее

GPRC5D and FCRH5 Targeted Therapies in MyelomaПодробнее

Future of BCMA-Targeted Therapies in Multiple MyelomaПодробнее

BCMA-Targeted CAR-Ts and Their Role in Late-Relapse Multiple MyelomaПодробнее

Integrating BCMA-targeted immunotherapies into challenging multiple myeloma casesПодробнее

Dr. Avigan on BCMA-Targeted CAR T-Cell Therapy in Multiple MyelomaПодробнее

BCMA-Directed Therapy in Multiple Myeloma: Assessing the Clinical ImpactПодробнее